Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beijing HuiLongGuan Hospital
With
Stanley Medical Research Institute
Evidences of high levels of Toxoplasma gondii antibodies in the serum and the cerebrospinal fluid (CSF) of individuals with schizophrenia have suggested that this organism might be involved in the etiopathogenesis of schizophrenia. The investigators hypothesize that antimicrobial therapy by using an add-on agent together with a well-proven neuroleptic may have favorable effects on a subgroup of schizophrenic patients.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently resides in Beijing, China
Diagnosis of schizophrenia or schizophreniform disorder
Duration of symptoms is no longer than 60 months
No history of treatment with antipsychotic medication or, if previously treated, a total lifetime usage of less than 14 days
Current psychotic symptoms are of moderate severity or greater as measured by one of the five psychotic items in the Brief Psychiatric Rating Scale (BPRS)
You may not be if
DSM-IV Axis I diagnosis other than schizophrenia or schizophreniform psychosis
Documented disease of the central nervous system that might interfere with the trial assessments (e.g., stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic infection)
Acute, unstable, and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension)
A clinically significant echocardiogram (ECG) abnormality in the opinion of the investigator
Pregnant or breastfeeding
Use of prohibited concomitant therapy
History of severe allergy or hypersensitivity
Dependence on alcohol or illegal drugs
Use of any of the following medications during the trial: antipsychotic medications other than risperidone; psychostimulants; or antidepressants
